ADCT

ADC Therapeutics SA

NYSE· Pharmaceutical Preparations· Inc. V8· CIK 0001771910 Biotech & Drug Discovery

$1.44 −0.16 (−10.00%)

Oct 23 4:00 PM ET · prev $1.60

Market cap

$204.3M

Micro cap

Consensus

Buy

67% Buy or better · 12 analysts

Median target

🔒 Subscribers only

1 year

−64.8%

from $4.09 · Oct 24

30 days

+11.6%

from $1.29

52-week range

$0.9600–4.88

−70% from high · low Aug 20

Avg volume 20D

1.60M

Oct 8 spike 5.55M

Short interest

6.90M

≈5.4% of shares · +27.9%

Days to cover

4.4

at average volume

Insider net

-$19.6M

0 buyers · 1 seller · 12 mo

Filing reports

analyzed by SecBot

SecBot read BULLISH 2 reports · 90 days

Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score

Avg score

·High conf. 2/2 ·Next Earnings date, Nov 10, 2026

Strongest BULLISH ADC Therapeutics announced a comprehensive capital restructuring: an $86.6M PIPE (12.9M shares at $1.42 +…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 10 ADC Therapeutics filed an S-3 shelf registration, signaling potentia…
S Mar 31 to Apr 2 3 days of insider sells: $19.6M by 1 insider, avg $3.34
R Jun 3 ADC Therapeutics announced topline results from the Phase 3 LOTIS-5…
A Jun 4 RBC Capital downgrades
A Jun 8 HC Wainwright & Co. downgrades
X Sep 30 Short interest jumps 27.9% to 6.90M
R Oct 13 ADC Therapeutics announced a comprehensive capital restructuring: an…

Signal stack

Where each data set points today.

InsidersBEARISH

1 insider sold $19.6M.
AnalystsBULLISH

8 of 12 rate it Buy or better.
Short sellersBUILDING

Short interest +27.9% to 6.90M shares. 4.4 days to cover, ≈5.4% of shares.
TrendUPTREND

15% above its 50-day average.

The Street

12 analysts

Buy 67% rate it Buy or better

Strong Buy4Buy4Hold3Sell0Strong Sell1

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Aug 17, 2026	Guggenheim MAINTAIN	MAINTAIN	Buy
Jun 8, 2026	HC Wainwright & Co. DOWNGRADE	DOWNGRADE	Neutral
Jun 4, 2026	RBC Capital DOWNGRADE	DOWNGRADE	Sector Perform
May 5, 2026	RBC Capital REITERATE	REITERATE	Outperform
May 5, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 10, 2026

Earnings date

🔒 Fresh data — subscribers only

Recent

Sep 30, 2026

Short interest

Short Interest: ADCT up 28% to 6.9M shares

Settlement 2026-09-30 | Days to cover: 4.37 | ≈5.40% of shares outstanding (est.)

Sep 3, 2026

Press release

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer…

Aug 14, 2026

Short interest

Short Interest: ADCT up 21% to 6.2M shares

Settlement 2026-08-14 | Days to cover: 6.30 | ≈4.84% of shares outstanding (est.)

Aug 13, 2026

Earnings date

ADCT Q2 2026 Earnings Scheduled — 2026-08-13

Aug 11, 2026

Earnings date

ADCT Q2 2026 Earnings Scheduled — 2026-08-11

Insider ledger

Form 4

bought · 0 insiders

$19.6M

sold · 1 insider

Date	Insider	Type	Value
Jun 30, 2026	GRAHAM PETER J Chief Legal Officer	AWARD	221,100 sh
Jun 30, 2026	MALLIK AMEET Chief Executive Officer	AWARD	675,000 sh
Jun 30, 2026	Zaki Mohamed Chief Medical Officer	AWARD	213,900 sh
Jun 30, 2026	Carmona Jose Chief Financial Officer	AWARD	203,700 sh
Jun 3, 2026	Squarer Ron Director	TAX W/H	$46.8K
Jun 3, 2026	Coughlin Timothy Director	TAX W/H	$38.8K
Jun 3, 2026	Hug Peter Director	TAX W/H	$6.6K
Jun 3, 2026	Monges Viviane Director	TAX W/H	$8.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data — subscribers only
Next Q	🔒 Fresh data — subscribers only
Current FY	🔒 Fresh data — subscribers only
Next FY	🔒 Fresh data — subscribers only